<DOC>
	<DOCNO>NCT02509117</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , PK PD PF-06751979 follow oral dos healthy adult healthy elderly subject .</brief_summary>
	<brief_title>First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year age 60 85 year , inclusive . Body Mass Index ( BMI ) 17.5 32 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Screening . Evidence personally sign date informed consent document indicate subject legally acceptable representative inform pertinent aspect study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Male subject partner currently pregnant ; male subject able father child unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product . Unwilling unable comply Lifestyle Guidelines describe protocol . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study . Any severe acute chronic medical psychiatric condition include recent ( within past year ) active suicidal ideation behavior laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
</DOC>